If you need more lookups,
subscriptions start at $34 USD/month.
Gerard Marek Location
Woodstock, IL, US
Gerard Marek Work
2025 -now Chief Medical Officer @ Gilgamesh Pharma Inc
2021 -now Chief Medical Officer @ Gilgamesh Pharmaceutical
2014 -2021 Global Medical Lead @ Astellas Pharma Global Development
2008 -2014 Project Director @ AbbVie/Abbott
2003 -2008 Chief Scientific Officer of Psychiatric Disorders Discovery Biology @ Eli Lilly and Company
2002 -2003 Associate Director @
2002 -2003 Associate Director @
1996 -2002 Assistant Professor @ Yale University School of Medicine; Dept. of Psychiatry
1995 -1996 Instructor in Psychiatry @ Yale University School of Medicine: Department of Psychiatry
1993 -1995 Post-doctoral fellow in Psychiatry @
1990 -1993 Psychiatric Resident @ Department of Psychiatry ; Yale School of Medicine
1989 -1990 Intership in Medicine @ Michael Reese Hospital and Medical Center
Gerard Marek Education
The University of Chicago Pritzker School of Medicine
M.D., Ph.D (Pharmacology (Ph.D.))
1982-1989
University of Iowa
B.S. (Psychology)
1978-1982
Gerard Marek Skills
Therapists
Clinical Trials
Psychiatry
CRO
In Vivo
Neuroscience
Neurology
Clinical Research
Regulatory Affairs
Drug Discovery
Medicine
Drug Development
Clinical Development
In Vitro
Endocrinology
Regulatory Submissions
Diabetes
Pharmacology
Research
Pharmaceutical Industry
Science
GLP
Biomarkers
FDA
IND
Gerard Marek Summary
Gerard Marek, based in Woodstock, IL, US, is currently a Chief Medical Officer at Gilgamesh Pharma Inc. Gerard Marek brings experience from previous roles at Gilgamesh Pharmaceutical, Astellas Pharma Global Development, AbbVie/Abbott and Eli Lilly and Company. Gerard Marek holds a 1982 - 1989 M.D., Ph.D in Pharmacology (Ph.D.) @ The University of Chicago Pritzker School of Medicine. With a robust skill set that includes Therapists, Clinical Trials, Psychiatry, CRO, In Vivo and more. Gerard Marek has 1 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Gerard Marek?
Find contact details for 700 million professionals.